Since 2016, the global IVD field has not been calm, and the giants are busy spending money on technology, mergers and acquisitions, and strategic alliances. According to China's medical device statistics, since the beginning of this year, there have been at least six cases of investment mergers and acquisitions in the domestic IVD field, innovation technology and capital alliance, channel, service provider and provider united, the industry's upstream and downstream chain is gradually opening.
Merck join hands with Merck Pfizer to join Agilent
On February 1 this year, pharmaceutical giant Abbott announced that it would spend $5.8 billion to acquire Alere Inc, a US diagnostic services provider. Through this transaction, Abbott is able to gain a global leading position in the field of bedside inspection, and also sit on the throne of the IVD Big Four.
However, this does not mean that other big names will reduce the big fat of 觊觎IVD.
On March 22, the German clinical diagnostic reagent company R-Biopharm announced a cooperation agreement with the Merck Group to promote the development and commercialization of new diagnostic reagents.
Baifa is a leading company in the field of clinical diagnosis in Germany. Its products cover infectious disease fecal diagnostics, infectious disease serum diagnostics, allergy diagnostics, oncology diagnostics and gastroenterology.
Since 2000, Baifa has obtained exclusive global distribution rights for enzymatic bioanalytical reagents developed by Roche (formerly Mannheim BOEHRINGER). In July last year, Baifa cooperated with Apogenix to reach a diagnostic test for tumor immunotherapy. In October, Baifa took over the tumor diagnostic reagent business of GeneWake in Munich.
Baifa has a subsidiary in China, and its office is located in Wangjing Science and Technology Park in Chaoyang District, Beijing.
Merck, you should remember, it has reached a global cancer strategic alliance with Pfizer, both of which have been promoting Pfizer's targeted oncology drug ceramide (cizotinib) in the Chinese market since January 1 this year.
In fact, there is also an important cooperation between the two sides to jointly develop tumor immunotherapy and PD-L1 inhibitor avelumab. Just a month ago, another big company, Agilent Technologies, joined in, working with Merck and Pfizer to develop a diagnostic test kit to screen patients for avelumab treatment.
In this way, Merck has formed another hand, and Merck Pfizer
Join hands with Agilent's landscape. It is still unknown whether the company with a tumor diagnostic reagent will join Merck Pfizer's Global Cancer Strategic Alliance.
Ningbo Jiamai Internet Technology CO., Ltd. , https://www.jmcuhyd.com